AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36177347
Drug: Tenofovir Disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir Disoproxil Fumarate (TDF) 300 mg
Trial: 33200722
Drug: MDT for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT for leprosy (600 mg rifampicin, 300 mg clofazimine, 100 mg dapsone monthly; 50 mg clofazimine and 100 mg dapsone daily)
Trial: 33200722
Drug: MDT for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT for leprosy plus itraconazole (100 mg twice daily)
Trial: 33596993
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg p.o. twice/day)
Trial: 33596993
Drug: Fermentable fibers
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermentable fibers (35 g/day)
Trial: 33596993
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin plus fiber
Trial: 34674404
Drug: Scheduled anticonvulsants
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled anticonvulsants and benzodiazepines as needed
Trial: 36102618
Drug: Lung volume
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung volume recruitment (LVR) used twice-daily
Trial: 34496899
Drug: Methylphenidate (MPH),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH), administered twice daily, dosage based on age and body weight.
Trial: 33446270
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy followed by physiotherapeutic scoliosis-specific exercise (PSSE)
Trial: 34403137
Drug: No-treatment (no-intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment (no-intervention and supplementation only, n=47)
Trial: 33478563
Drug: Robotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic therapy (1 hour per day for 10 days)
Trial: 33478563
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard of care therapy only)
Trial: 35042638
Drug: Mobile phone
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone reminders (SMS and follow-up calls) sent three days to and on the due date of the child's schedule for the 1st, 2nd, and 3rd doses of the pentavalent vaccine.
Trial: 34487764
Drug: Elective nodal
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective nodal irradiation (ENI) using ultra-hypofractionated radiation (UHRT) (25 Gy in 5 weekly fractions)
Trial: 39702151
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 10 mg
Trial: 33522839
Drug: Nitrofurantoin treatment
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin treatment
Trial: 33522839
Drug: Fosfomycin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin treatment
Trial: 33658841
Drug: Pregabalin (300-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (300-450 mg/day)
Trial: 32842052
Drug: E2/P4 hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/P4 hormone therapy (TX-001HR)
Trial: 34788454
Drug: Zao Ren
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zao Ren An Shen (ZRAS) capsule
Trial: 36377643
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Zika vaccine (6 antigen units)
Trial: 36377643
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Zika vaccine (3 antigen units)
Trial: 32278858
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d of purified anthocyanins
Trial: 32278858
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of purified anthocyanins
Trial: 33442904
Drug: Iron infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron infusion (iron (iii)-hydroxide sucrose)
Trial: 32700220
Drug: Peer coach-led
RxNorm normalized name: coachwhip stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer coach-led intervention for chronic pain (6 months, contact twice per month)
Trial: 33072197
Drug: Cerebrolysin, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin, 50 mL per day for ten days, followed by two treatment cycles with 10 mL per day for ten days
Trial: 35120184
Drug: Weekly assessments
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly assessments of Dizziness Handicap Inventory (DHI), MdDS Balance Rating Scale (MBRS), and Hospital Anxiety and Depression Scale (HADS)
Trial: 36282051
Drug: Intralesional PPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional PPD injections
Trial: 33020098
Drug: Transcranial magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial magnetic stimulation (TMS) therapy for depression
Trial: 33932411
Drug: poly (I:C)
RxNorm normalized name: C.I. acid blue 324
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: poly (I:C) treatment
Trial: 33159796
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (60, 40, 30, 20, 15, and 10 mg daily for 1 week each, followed by 5 mg daily for 18 weeks)
Trial: 32921501
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose pitavastatin (2 mg/d)
Trial: 35022459
Drug: Preemptive ultrasound-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive ultrasound-guided transversus abdominis plane (TAP) block with 20 cc of ropivacaine 0.25%
Trial: 35022459
Drug: Postoperative ultrasound-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative ultrasound-guided transversus abdominis plane (TAP) block with 20 cc of ropivacaine 0.25%
Trial: 33471039
Drug: Liraglutide 3
RxNorm normalized name: liraglutide 3.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3 mg/d
Trial: 32413238
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (5-mg olanzapine ODT)
Trial: 32413238
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (5-mg olanzapine ODT)
Trial: 37258803
Drug: Dapagliflozin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin + Sitagliptin + Metformin ER (10 mg + 100 mg + 1000 mg)
Trial: 37258803
Drug: Sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin + Metformin SR (100 mg + 1000 mg)
Trial: 37258803
Drug: Dapagliflozin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin + Metformin ER (10 mg + 1000 mg)
Trial: 33932394
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 5 μg.mL‐1 sufentanil (group S) with 30 mL of 0.5% bupivacaine
Trial: 33932394
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 100 μg.mL‐1 dexmedetomidine (group D) with 30 mL of 0.5% bupivacaine
Trial: 33771763
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12, 10^9 colony-forming units, orally, once daily for 6 months
Trial: 37645033
Drug: Aripiprazole as
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole as adjunctive therapy with valproate sodium
Trial: 37645033
Drug: Risperidone as
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone as adjunctive therapy with valproate sodium
Trial: 34927590
Drug: Wearable activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable activity tracker + 6 weekly behavioral support emails
Trial: 616625220
Drug: EOAP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOAP regimen combined with Chansu injection (20 ml/d, intravenous drip, on d 1-14)
Trial: 39480221
Drug: Intravenous access
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous access
Trial: 32022827
Drug: Risk reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk reduction through family therapy (RRFT)
Trial: 32454417
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2/day on days 1, 22 and 43 of radiotherapy)
Trial: 32454417
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m2 loading dose, 250 mg/m2/week during radiotherapy)
Trial: 35186114
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 µg/kg before skin incision for 10 min, followed by intravenous infusion at 0.4 µg·kg‐1·h‐1 until 30 min before surgery.
Trial: 34672064
Drug: 0.33% hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.33% hydrocortisone sodium phosphate solution
Trial: 34672064
Drug: 0.001% hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.001% hydrocortisone sodium phosphate solution
Trial: 35724496
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation (CR) plus treatment-as-usual (TAU)
Trial: 35477377
Drug: Low-dose intrathecal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intrathecal morphine (100 µg) with 12.5 mg of 0.5% hyperbaric bupivacaine
Trial: 35477377
Drug: Sufentanil PCIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil PCIA (100 µg) with 12.5 mg of 0.5% hyperbaric bupivacaine
Trial: 35477377
Drug: Low-dose intrathecal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intrathecal morphine (100 µg)
Trial: 35477377
Drug: Sufentanil PCIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil PCIA (100 µg)
Trial: 38717038
Drug: Once-weekly somatrogon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly somatrogon (0.66 mg/kg/week)
Trial: 38717038
Drug: Once-daily somatropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily somatropin (0.24 mg/kg/week)
Trial: 38053515
Drug: Once-weekly somatrogon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly somatrogon
Trial: 34476342
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg) plus Vitamin D (400 IU) supplementation
Trial: 34476342
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg) plus Vitamin D (400 IU) supplementation with personal supplements
Trial: 35316819
Drug: Nerve Growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve Growth Factor (NGF) injection
Trial: 32044905
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO, n = 38, 2 g day‐1 EPA + DHA)
Trial: 32777896
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone (0.1 mg kg–1) administered 20 min before intubation
Trial: 35974309
Drug: alfentanil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil and remimazolam 0.1 mg/kg (AR1 group)
Trial: 35974309
Drug: alfentanil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil and remimazolam 0.15 mg/kg (AR2 group)
Trial: 35974309
Drug: alfentanil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil and remimazolam 0.2 mg/kg (AR3 group)
Trial: 34106250
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS under placebo medication
Trial: 34106250
Drug: Cathodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal tDCS under placebo medication
Trial: 34106250
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS under citalopram (20 mg/40 mg)
Trial: 34106250
Drug: Cathodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal tDCS under citalopram (40 mg)
Trial: 34106250
Drug: Cathodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal tDCS under citalopram (20 mg)
Trial: 33772124
Drug: Active intervention
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active intervention group (AG) with multiple interventions including training courses for nurses on dental health, oral health-related information cards (OHICs), and atraumatic restorative treatment (ART)-trained dentists
Trial: 33772124
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) receiving a 45-minute lecture on oral health
Trial: 34747807
Drug: MIRE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIRE therapy
Trial: 32766852
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy for CNS+ patients in the international randomized phase 3 trial Inter-B-NHL-ritux 2010
Trial: 33908815
Drug: Luteinising hormone
RxNorm normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinising hormone (LH) supplementation (Group A)
Trial: 32186587
Drug: Conventional Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Oxygen Therapy
Trial: 32876405
Drug: Clonidine 0.2
RxNorm normalized name: CLONIDINE 0.2MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.2 mg (group C)
Trial: 32876405
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg (group P)
Trial: 33977835
Drug: Varied ROM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varied ROM (daily alternation between INITIALROM and FINALROM)
Trial: 34478028
Drug: IV milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV milrinone (0.5 µg/kg/min, median duration of infusion 5 days)
Trial: 34996347
Drug: WBF-011 (5-strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBF-011 (5-strain novel probiotic formulation)
Trial: 35586668
Drug: PD-1/PD-L1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 treatment
Trial: 35586668
Drug: PD-1/PD-L1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitor chemotherapy
Trial: 32761445
Drug: Oral leukoplakia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral leukoplakia cases with etiological factors (smoking, alcohol consumption)
Trial: 32617646
Drug: tolcapone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone (100 mg TID for 5 days)
Trial: 33048154
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (n=153) with 4 weekly, 4 biweekly, and 3 monthly counseling sessions and choice of cessation medication.
Trial: 33048154
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n=150) with 4 weekly counseling sessions and medication advice.
Trial: 33048154
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (n=153) participants reporting cessation medication use.
Trial: 33048154
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n=150) participants reporting cessation medication use.
Trial: 33048154
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group adverse events (n=153).
Trial: 33048154
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group adverse events (n=150).
Trial: 32441857
Drug: Buspirone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (15 mg thrice daily)
Trial: 35550374
Drug: Intrarectal 10-mg
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal 10-mg diazepam suppository
Trial: 32689594
Drug: Rivaroxaban 15mg
RxNorm normalized name: RIVAROXABAN 15MG TAB
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 15mg daily
Trial: 32689594
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg daily
Trial: 35813411
Drug: Predictive nursing
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive nursing combined with early drinking water therapy
Trial: 35729430
Drug: Canagliflozin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (100 mg, n=113)
Trial: 35729430
Drug: Glimepiride (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (starting dose: 0.5 mg, n=120)
Trial: 33499076
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene board game intervention (60-min sessions, twice a week)
Trial: 35176533
Drug: CALAS 20
RxNorm normalized name: CALASPARGASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALAS 20 mg three times daily for seven days
Trial: 35176533
Drug: CALAS 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALAS 40 mg three times daily for seven days
Trial: 35176533
Drug: CALAS 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALAS 80 mg three times daily for seven days
Trial: 32781283
Drug: Huoxiang Zhengqi
RxNorm normalized name: HYPOCHLOROUS ACID 100 mg in 500 mL EXTRACORPOREAL LIQUID [Huoting slight acid hypochlorite disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules combined with western medicine
Trial: 32781283
Drug: Lianhua Qingwen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lianhua Qingwen granules combined with western medicine
Trial: 35435017
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (<2 g of sodium)
Trial: 34477291
Drug: Inpatient Treatment-as-Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient Treatment-as-Usual (TAU)
Trial: 32894190
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (TA)
Trial: 32894190
Drug: Medication (MC)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (MC)
Trial: 35175622
Drug: CBD25 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD25 (25 mg/kg/day)
Trial: 35175622
Drug: CBD50 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD50 (50 mg/kg/day)
Trial: 36255525
Drug: 0.125% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% levobupivacaine at 8 mL/h
Trial: 36255525
Drug: 0.25% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% levobupivacaine at 8 mL/h
Trial: 34487151
Drug: Pradefovir 75
RxNorm normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradefovir 75 mg
Trial: 34488701
Drug: Antipsychotics (AP)
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics (AP) withdrawal (pipamperone or risperidone); dose reduced by 25% every 4 weeks.
Trial: 34488701
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group); dose remains unaltered.
Trial: 32957204
Drug: Conical implants
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conical implants
Trial: 32957204
Drug: Straight implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straight implants
Trial: 34280472
Drug: miR‐185‐5p and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miR‐185‐5p and miR‐425‐5p expression levels measured before radiation therapy